Nukleon Nuclear Technology

What Nukleon Nuclear Technology does

Nukleon Nuclear Technology (legal name: Nukleon Nükleer Teknoloji Araştırma San. ve Tic. Ltd. Şti) is a privately held Turkish limited company founded in 2010 and headquartered at Yıldız Technical University Teknopark in Esenler, Istanbul. It operates a 2370 m2 radiopharmaceutical production facility with 1200 m2 of closed production area operating under Current Good Manufacturing Practices (cGMP) and Good Radiopharmacy Practices (GRP). The facility was approved in 2011 by the Turkish Atomic Energy Authority (now Nükleer Düzenleme Kurumu) and the Ministry of Health, and is ISO 9001:2015 and ISO 14001:2015 certified. The company employs 25 professionals.

The company's core manufactured product is FLORON G, a domestically produced (18F) Fluorodeoxyglucose (FDG) solution at 1733 MBq/ml for PET imaging in oncology, cardiology, neurology, and infection diagnostics. Beyond its own FDG production, Nukleon operates as the authorized or exclusive distributor in Turkey for six international nuclear medicine brands: ITM (Ge-68/Ga-68 generators, iQS-TS synthesizer, n.c.a. Lu-177), Eckert & Ziegler BEBIG (HDR afterloaders, brachytherapy sources and seeds, applicators, SagiPlan TPS), SHINE (n.c.a. Lu-177 ILUMIRA), CMR (stable isotopes, PET precursors), MTTI (EBTATE), and TRIMT (Trivehexin). The portfolio spans diagnostic and therapeutic radiopharmaceuticals, theranostic peptides (PSMA I&T, PSMA-11, PSMA-617, DOTA-TATE, DOTA-TOC, EBTATE, Trivehexin), synthesis instruments, HPLC quality control, brachytherapy devices, and synthesis cassettes and reagents.

Nukleon makes money through a dual B2B model: direct sales of domestically produced FLORON G FDG to hospitals and nuclear medicine departments via a dealer network, and authorized distribution of imported radiopharmaceuticals, equipment, and consumables to Turkish nuclear medicine departments, PET imaging centers, radiotherapy clinics, and cancer treatment centers. The pricing is not publicly disclosed, orders are placed via a dealer/customer order form system, and no external funding rounds have been disclosed. The company remains a domestic, founder- or management-owned operator within the Turkish nuclear medicine market.

Name

Nukleon Nuclear Technology

Legal name

Nukleon Nükleer Teknoloji Araştırma San. ve Tic. Ltd. Şti

Website

https://nukleon.com.tr

Company type

Private

Founded year

2010

Operating status

Operating

Headcount range

11–50 employees

Short description

Nukleon Nuclear Technology is a privately held Turkish limited company that manufactures (18F) FDG radiopharmaceuticals at a cGMP facility in Istanbul and distributes international nuclear medicine brands, theranostic peptides, and brachytherapy equipment to hospitals and PET imaging centers across Turkey.

Ownership category

akta.pro rank

Product category

Radiopharmaceuticals

NAICS

Medical Equipment and Supplies Manufacturing (3391), Irradiation Apparatus Manufacturing (334517), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (3345)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro industry

PRIMARYHLAIAGAF

Radiopharmaceutical CDMO & Manufacturing (GMP Fill-Finish)

Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine

SECONDARYHLAIAGAE

Radiopharmacy Compounding & Dispensing (Hospital/Commercial)

Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine

SECONDARYHLAIAJAI

Radiopharmaceutical & Nuclear Medicine Distributors

Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Distribution & Wholesaling

SECONDARYEUAKAIAE

Nuclear Medicine Imaging Tracers & PET/SPECT Supply Chain (FDG, Ga-68, logistics/cold chain)

Energy, Utilities & Environment/Nuclear Energy/Nuclear Materials, Radiation Services & Isotopes (Medical/Industrial)

SECONDARYEUAKAIAD

Radiation Therapy Isotopes & Sources (Brachytherapy seeds, sealed sources for oncology)

Energy, Utilities & Environment/Nuclear Energy/Nuclear Materials, Radiation Services & Isotopes (Medical/Industrial)

SECONDARYHLAIAGAH

Radionuclide Supply Chain & Logistics (Shielding/Transport/Distribution)

Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine

Keywords

• Radiopharmaceutical manufacturing
• Nuclear medicine products
• PET imaging diagnostics
• Brachytherapy solutions
• Radiopharmaceutical distribution

Headquarters

HQ city

Istanbul

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Radiopharmaceutical Product Sales: Sale of domestically produced radiopharmaceuticals including FLORON G (18F-FDG) to hospitals and nuclear medicine departments. Production at company's own cGMP facility in Istanbul.
2. Authorized Distribution of International Nuclear Medicine Products: Revenue generated as authorized/distributor for international nuclear medicine brands including ITM (generators, synthesizers), Eckert & Ziegler BEBIG (HDR afterloaders, brachytherapy sources), SHINE (n.c.a. Lu-177), MTTI (EBTATE), CMR (isotopes), and TRIMT (Trivehexin) in the Turkish market.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels2 records

Core offering

Nukleon Nuclear Technology is a Turkish radiopharmaceutical manufacturer that produces FLORON G (18F-FDG) at its cGMP-compliant facility in Yıldız Technical University Technopark, Istanbul. The company also operates as an authorized distributor in Turkey for international nuclear medicine brands including ITM, Eckert & Ziegler BEBIG, SHINE, MTTI, CMR, and TRIMT, supplying diagnostic and therapeutic radiopharmaceuticals, brachytherapy devices, theranostic peptides, synthesis instruments, and related consumables to hospitals, nuclear medicine departments, and PET imaging centers.

Product overview

Nukleon Nükleer Teknoloji Araştırma San. ve Tic. Ltd. Şti is a Turkish radiopharmaceutical manufacturer and distributor operating in the nuclear medicine sector. Its own manufactured core product is FLORON G (18F-Fluorodeoxyglucose), produced at its cGMP-compliant facility in Yıldız Technical University Technopark, Istanbul. Beyond its own FDG production, the company serves as an authorized distributor in Turkey for a portfolio of internationally produced radioactive products, medical instruments, peptides, and consumables from partner manufacturers including ITM (Ge-68/Ga-68 generators, iQS-TS synthesizer, n.c.a. Lu-177), Eckert & Ziegler BEBIG (HDR brachytherapy afterloaders, radioactive seeds, applicators, treatment planning systems), SHINE (n.c.a. Lu-177 ILUMIRA), CMR (stable isotopes, PET chemicals), MTTI (EBTATE), and TRIMT GmbH (Trivehexin). The product portfolio spans radioactive pharmaceuticals (FDG, Lu-177, Ga-68, I-125 seeds, Ru-106 applicators, Co-60, Ir-192 sources), theranostic peptides (PSMA I&T, PSMA-11, PSMA-617, Dota-TATE, Dota-TOC, EBTATE, TRIVEHEXIN), synthesis instruments (iQS-TS synthesizer, HPLC quality control), brachytherapy devices (SagiNova HDR afterloader, SagiPlan TPS, HDR applicators), and associated consumables (Ga-68 and Lu-177 synthesis cassettes, HCl elution medium).

Differentiator

Problem solved

Functional benefit

Brands

• FLORON G: FLORON G 1733 MBq/ml I.V Solution for Injection — the trade name for the company's (18F) Fluorodeoxyglucose (FDG) radiopharmaceutical product.

Products and services

• FLORON G 1733 MBq/ml I.V Solution for Injection Type I colourless glass vial of (18F)Fluorodeoxyglucose solution at 1733 MBq/ml radioactive concentration, stored in a tungsten shield, with minimum 95% radiochemical purity and 12-hour shelf life from end of synthesis. Used with PET scanners for diagnostic imaging of abnormal glucose metabolism in oncology, cardiology, neurology, and infection cases. Produced daily except Sunday.
• Ge-68/Ga-68 Generator Germanium-68 / Gallium-68 generator producing positron-emitting Ga-68 isotope (68-minute half-life) by radioactive decay of Ge-68 (271-day half-life), enabling cyclotron-independent in-house radiopharmaceutical production with GMP-approved metal-free column design and 0.05M low-acidic eluent.
• n.c.a. Lutetium-177 (ILUMIRA) Non-carrier-added Lutetium-177 radiopharmaceutical produced under cGMP, meeting and exceeding European Pharmacopoeia requirements. When paired with a cancer-seeking molecule, it delivers targeted radiotherapy by emitting short-range radiation that selectively destroys cancer cells.
• I-125 Eye Seeds (IsoSeed®) IsoSeed® I25.S16 I-125 radioactive seeds for treatment of eye tumors such as uveal melanomas and retinoblastomas, with apparent activities covering a wide range up to 25 mCi, suitable for medium-sized to large eye tumors.
• I-125 Prostate Seeds Radioactive I-125 seeds intended for the permanent treatment of localized prostate cancer, delivered as sterile loose IsoSeeds or sterile IsoStrand seeds and implanted using needles.
• I-125 Brain Seeds I-125 seeds intended for temporary or permanent treatment of localized brain tumors including WHO graded I-IV circumscribed glial tumors and brain metastases, implanted using closed double catheters with inner diameter of ≥1 mm.
• Ru-106 Eye Applicator Ruthenium-106 eye applicator for eye-preserving treatment of uveal melanoma and retinoblastoma with a 373.6-day half-life, requiring no assembly and only sterilization before use; can be used multiple times over a one-year period.
• Co-60 Source Cobalt-60 radioactive source, a well-established and clinically proven isotope for all HDR brachytherapy treatments, offering lower dose to organs at risk compared to Ir-192.
• Ir-192 Source Miniaturized Iridium-192 radioactive source in clinical use for over 10 years with a 4-month working life due to its short half-life and source transfer quantity of 25,000.
• iQS-TS Fully Automated Theranostics Synthesizer Fully automated cassette-based theranostics synthesizer for routine preparation of radiolabeled biomolecules using predefined GMP-compliant labeling protocols for peptides, antibodies, small molecules, or hormones targeting somatostatin receptors, PSMA, bone tissue, bombesin receptors, or integrins. RFID-tagged consumables enable automated recognition, status reporting, and documentation.
• HPLC Quality Control Solution State-of-the-art radio-HPLC configuration for analysis of radiolabeled biomolecules according to Ph. Eur./USP standards, featuring an integrated quaternary HPLC pump, UV/VIS and radio detectors, latest Chromstar workstation, and temperature-controlled fully shielded column compartment.
• SagiNova® HDR Afterloader Brachytherapy Instrument HDR afterloader system designed for brachytherapy applications with up to 50 channels, featuring automatic catheter/applicator length measurement for improved patient safety. Supports both Ir-192 and Co-60 radioactive sources and integrates with SagiPlan® treatment planning system.
• SagiPlan® Treatment Planning System Comprehensive treatment planning software (TPS) for all HDR brachytherapy applications including real-time prostate treatment, with a modern multilingual user interface, advanced planning features, and customizable parameter layouts for efficient workflow.
• HDR Applicators Comprehensive portfolio of applicators for HDR brachytherapy covering gynecological cancers as well as prostate, breast, esophagus, nasopharynx, lung, bronchus, lip, and oral cavity treatments.
• PSMA I&T Precursor for radio-metal labeling (Ga-68 and Lu-177) containing the DOTAGA chelate, and a ligand for PSMA (prostate-specific membrane antigen) targeting prostate cancer imaging.
• PSMA-11 Preferred tracer for Ga-68 labeling used in PET imaging of prostate cancer (PCa).
• PSMA-617 PSMA ligand containing the DOTA chelate for radiolabeling, targeting prostate-specific membrane antigen for prostate cancer theranostics.
• Dota-TATE Precursor for radiolabeling (Ga-68 and Lu-177) and ligand for somatostatin receptors, used in neuroendocrine tumor imaging and therapy.
• Dota-TOC Precursor for radiolabeling (Ga-68 and Lu-177) and ligand for somatostatin receptors.
• EBTATE Somatostatin analog incorporating Evans Blue in its backbone which increases albumin residence, prolonging blood half-life and enhancing theranostic bioavailability for neuroendocrine tumor targeting.
• TRIVEHEXIN (αvβ6 Integrin) Alpha-v-beta-6 (αvβ6) integrin targeting peptide used in diagnosis of pancreatic ductal adenocarcinoma (PDAC), head and neck cancers (HNSCC), idiopathic pulmonary fibrosis (IPF), and non-small cell lung cancers (NSCLC).
• Ga-68 Synthesis Cassette and Reagents (Ga-68 Maxi-Set) Single-use low bioburden cassette for Ga-68 synthesis consisting of three manifolds, luer connectors, tubings, hypodermic needles, reaction vial, syringe, C18 light cartridge, and RFID tag, supplied as a complete box for 10 synthesis operations (manufactured according to ICH Q7, GMP for API).
• Lu-177 Synthesis Cassette and Reagents (Lu-177 Maxi-Set) Single-use low bioburden cassette for Lu-177 synthesis consisting of two manifolds, luer connectors, tubings, hypodermic needles, reaction vial, syringe, and RFID tag, supplied as a complete box containing cassettes and reagents for 10 synthesis operations (manufactured according to ICH Q7, GMP for API).
• HCl Elution Medium 0.05 M HCl (4.15 mL) vial solution used to elute the Ge-68/Ga-68 generator, supplied in packs of five.

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Six partnerships are on record, tiered core and minor.

• ITM Isotopen Technologien München AGcoreChannel Partner/ Reseller/ DistributorNukleon serves as the authorized distributor of ITM in Turkey for high-efficiency non-GMP or GMP-grade Ge-68/Ga-68 generators, highly pure no-carrier-added EndolucinBeta (n.c.a. Lu-177), and the user-friendly iQS-TS synthesis device with all accessories performing synthesis in 17 minutes including elution.
• Eckert & Ziegler BEBIGcoreChannel Partner/ Reseller/ DistributorNukleon serves as the exclusive distributor of Eckert & Ziegler BEBIG for HDR Afterloader devices and all accessories with treatment planning systems, Co-60 and Ir-192 radioactive sources, I-125 labeled eye, prostate and brain seeds, and Ru-106 eye plaques in the Turkish market.
• MTTI (Molecular Targeting Technologies, Inc.)coreChannel Partner/ Reseller/ DistributorNukleon serves as the exclusive distributor of MTTI in Turkey. MTTI is a clinical-stage company developing EBTATE, a selective radiotherapeutic targeting neuroendocrine tumors, representing cutting-edge therapeutic radiopharmaceutical technology.
• CMR (Center of Molecular Research)coreChannel Partner/ Reseller/ DistributorNukleon serves as the authorized distributor of CMR (founded 1993) in Turkey. CMR is one of the world's largest manufacturers and suppliers of Oxygen-18 water and stable isotopes, also producing reagent kits, PET tomography chemicals, and PET precursors under GMP conditions.
• TRIMT GmbHminorChannel Partner/ Reseller/ DistributorNukleon serves as the authorized distributor of TRIMT's Trivehexin product (alpha-v-beta-6 integrin targeting peptide) in Turkey. TRIMT is a science and data-driven company focused on pharmaceutical and clinical developments addressing unmet clinical needs.
• SHINEcoreChannel Partner/ Reseller/ DistributorNukleon serves as the authorized distributor of SHINE's NCA (Non-Carrier-Added) Lutetium-177 (n.c.a. Lu-177) branded as ILUMIRA in the Turkish market. ILUMIRA is a targeted cancer therapeutic isotope produced at SHINE's U.S. facility under cGMP, meeting and exceeding European Pharmacopoeia requirements.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Lantheus Holdings: U.S.-based radiopharmaceutical company with a portfolio including FDG and PSMA-targeted diagnostics. Comparable to Nukleon as a radiopharmaceutical manufacturer serving oncology and cardiology PET imaging customers in the same diagnostic modalities.
• Eczacıbaşı-Monrol: Turkey's largest radiopharmaceutical producer (FDG and other PET/SPECT tracers) operating multiple production sites. Most direct comparable to Nukleon as a fellow domestic Turkish cGMP radiopharma manufacturer and distributor of nuclear medicine products.
• SHINE Technologies: U.S. producer of n.c.a. Lu-177 (ILUMIRA) and other medical isotopes. Comparable to Nukleon as a principal whose Lu-177 Nukleon distributes in Turkey, and as a fellow nuclear medicine isotope producer addressing the same oncology theranostics customers.
• ITM Isotopen Technologien München AG: Manufacturer of Ge-68/Ga-68 generators, n.c.a. Lu-177 (EndolucinBeta) and theranostic synthesizers (iQS-TS). Comparable to Nukleon both as a partner-principal supplying products Nukleon distributes and as a specialist radiopharma manufacturer addressing similar therapeutic indications.

Others

• Cardinal Health Nuclear & Precision Health Solutions: One of the largest U.S. radiopharma distributors serving hospitals with unit-dose radiopharmaceuticals and SPECT/PET agents. Comparable to Nukleon as a broad nuclear medicine distributor operating at scale.

Broad incumbents

• Curium Pharma: One of the world's largest nuclear medicine companies, manufacturing and distributing a broad portfolio of diagnostic and therapeutic radiopharmaceuticals. Comparable as a global radiopharmaceutical manufacturer competing for the same hospital customers and theranostics demand Nukleon addresses in Turkey.
• GE HealthCare (PETNET Solutions): Operates a global network of PET radiopharmacy manufacturing sites (including FDG) and supplies imaging agents and nuclear medicine equipment. Comparable to Nukleon as a vertically integrated nuclear medicine manufacturer-distributor serving hospital imaging customers.
• Bayer (Radiopharmaceuticals / Telix-adjacent portfolio): Through its prior radiopharma franchise (Xofigo/radium-223) and ongoing precision oncology investments, Bayer competes in the same therapeutic radiopharmaceutical space that Nukleon's distributed Lu-177 and PSMA products address.
• Eckert & Ziegler: Global manufacturer of brachytherapy seeds, HDR afterloaders (SagiNova), radioactive sources and radiopharma components — the same lines Nukleon distributes in Turkey. Comparable as both a peer principal and a broader incumbent in radiation therapy and nuclear medicine isotopes.

Emerging players

• Telix Pharmaceuticals: Commercial-stage radiopharma company focused on PSMA-targeted imaging and therapy for prostate cancer. Comparable to Nukleon as a theranostics player whose PSMA pipeline competes with the PSMA products Nukleon distributes (PSMA-11, PSMA-617, PSMA I&T).

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/nukleon-nuclear-technology

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Nukleon Nuclear Technology